Regenxbio Inc (NASDAQ:RGNX)
| 19.64 Delayed Data As of May 19 |  +0.07 / +0.36%Today’s Change | 18.69 Today|||52-Week Range 46.46 | -39.94% Year-to-Date |
Latest RGNX News | Press Releases
No recent news for Regenxbio Inc.
Today’s Trading
| Previous close | 19.57 |
| Today’s open | 19.41 |
| Day’s range | 18.70 - 19.89 |
| Volume | 18,693 |
| Average volume (3 months) | 425,576 |
| Market cap | $898.9M |
Data as of 4:02pm ET, 05/19/2022
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -258.29% |
| Earnings growth (next 5 years) | +11.81% |
| Revenue growth (last year) | +204.30% |
| P/E ratio | 8.5 |
| Price/Sales | 3.05 |
| Price/Book | 1.17 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MORFMorphic Holding Inc | -0.62 | -2.70% |
| SAVACassava Sciences Inc | +1.79 | +8.03% |
| ---- | ||
| IMGNImmunoGen Inc | +0.02 | +0.57% |
Data as of 5:53pm ET, 05/19/2022
Financials
| Next reporting date | August 10, 2022 |
| EPS forecast (this quarter) | -$1.41 |
| Annual revenue (last year) | $470.3M |
| Annual profit (last year) | $127.8M |
| Net profit margin | 27.18% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Rockville, Maryland |
Forecasts
